1 | Study | 3.61% | |
2 | Intermittent | 2.41% | |
3 | COVID-19 | 2.41% | |
4 | BMC | 1.2% | |
5 | Clinical | 1.2% | |
6 | UH | 1.2% | |
7 | Intraepithelial | 1.2% | |
8 | March | 1.2% | |
9 | Federal | 1.2% | |
10 | Ethnic | 1.2% | |
11 | Korea | 1.2% | |
12 | Como | 1.2% | |
13 | Upfront | 1.2% | |
14 | Polatuzumab | 1.2% | |
15 | Global | 1.2% | |
16 | Anuzis | 1.2% | |
17 | Vocal | 1.2% | |
18 | Post-transplant | 1.2% | |
19 | Yonhap | 1.2% | |
20 | Examines | 1.2% | |
21 | Tribune | 1.2% | |
22 | Verde | 1.2% | |
23 | Groups | 1.2% | |
24 | Using | 1.2% | |
25 | Medicine | 1.2% | |
26 | YONHAP | 1.2% | |
27 | Racial | 1.2% | |
28 | COVID | 1.2% | |
29 | NOTICIAS | 1.2% | |
30 | Affordable | 1.2% | |
31 | Cruz | 1.2% | |
32 | Kate | 1.2% | |
33 | Approach | 1.2% | |
34 | Cervical | 1.2% | |
35 | III | 1.2% | |
36 | Intelligence | 1.2% | |
37 | Positive | 1.2% | |
38 | Lymphoproliferative | 1.2% | |
39 | Grupo | 1.2% | |
40 | Signatures | 1.2% | |
41 | Treatment | 1.2% | |
42 | YA | 1.2% | |
43 | Lesion | 1.2% | |
44 | Waco | 1.2% | |
45 | Newer | 1.2% | |
46 | Multicenter | 1.2% | |
47 | Sounds | 1.2% | |
48 | Report | 1.2% | |
49 | Vedotin | 1.2% | |
50 | Case | 1.2% | |
는 분류, 데이터 기준으로 의 기사에서 의 고유명사 데이터를 통해 생성되었습니다.
|